UPDATE: Cantor Fitzgerald On Kamdon Holdings Also Notes 'From a stock perspective, we think this update removes the binary clinical risk from the story and turns the focus toward the commercial opportunity, where we continue to see upside over time'

Do you like seeing these details as to why an analyst recommended a stock? What could we do to make this product better? Let us know by emailing newsdesk@benzinga.com

Benzinga · 11/12/2019 14:20